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Abstract 
Background: Corticosteroids are preferred to treat patients with active IgA nephropathy (IgAN), and beneficial 
effects from the short-term use of corticosteroids have been confirmed. However, a large number of patients will pro-
gress to end-stage renal disease after a long time follow-up. This study aimed to evaluate kidney disease progression 
and risk factors on kidney survival in IgAN patients receiving steroids treatment.
Methods: Two hundred biopsy-proven IgAN patients who received corticosteroid therapy were enrolled and fol-
lowed for a median period of 63.33 months. Risk factors on kidney survival were retrospectively investigated by the 
Cox proportional hazards model.
Results: Of the two hundred patients, twenty patients showed progression of renal impairment at the end of 
follow-up. The median and interquartile range values for initial serum creatinine were 89.2 and 68.08–121.35 µmol/L, 
respectively. Multivariate Cox regression analyses revealed that relapse, non-remission, time-averaged eGFR (TA-eGFR), 
and time-averaged serum albumin (TA-ALB) were independently associated with the kidney progression. Those with 
TA-ALB levels <35 g/L and TA-eGFR levels <60 mL/min/1.73 m2 were less likely to recover from kidney progression. 
Patients were more likely to show kidney function deterioration, when they had non-remission or relapse after corti-
costeroids treatment.
Conclusion: This study demonstrated that relapse, non-remission, TA-eGFR, and TA-ALB could serve as independent 
predictors of long term prognosis of IgAN patients receiving corticosteroid therapy.
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Background
IgA nephropathy (IgAN) is the most commonly occur-
ring glomerulopathy and very likely progresses to 
end-stage renal disease (ESRD) worldwide [1–4]. The 
pathogenesis of IgAN is still unclear, and no specific 
treatment is established [5]. Clinically, proteinuria is the 
most powerful predictor of poor kidney outcome, and 
reduction of proteinuria is associated with improved kid-
ney survival [2, 3, 6–8]. Thus corticosteroids seem to be a 
good treatment, for its function of ameliorating proteinu-
ria and protecting against kidney deterioration [9–11].
There has been widespread interest in corticosteroid 
therapy for IgAN. Studies have reported that prednisone 
can reduce urinary protein, protect kidney function, 
and delay the progress of IgAN [9–11]. Kidney disease: 
improving global outcomes (KDIGO) clinical practice 
guideline for glomerulonephritis suggest that patients 
with persistent proteinuria >1 g/day, despite 3–6 months 
of optimized supportive care [including angiotensin con-
verting enzyme inhibitor (ACE-I) or angiotensin II recep-
tor blocker (ARB) and blood pressure control], and GFR 
>50  mL/min per 1.73  m2, receive a 6-month course of 
corticosteroid therapy [12].
Open Access
*Correspondence:  shanmou_renji@126.com 
†Yanhong Yuan and Qin Wang contributed equally to this work
Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji 
Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian 
Road, Shanghai 200127, China
Page 2 of 8Yuan et al. J Transl Med  (2015) 13:186 
Beneficial effects from the short-term use of corticos-
teroids were reported in randomized control trial stud-
ies (RCTs) [13, 14]. However, in clinic, kidney function 
deterioration still occurred with a considerable amount 
of patients receiving prednisone. Moreover, the results of 
RCTs in adult patients are controversial, because of dif-
ferent outcomes consideration, small sample size or too 
short follow-up periods for a slowly progressing disease 
[15–17].
Therefore we retrospectively investigated the influence 
of clinical and laboratory potential risk factors on kidney 
survival in 200 patients receiving steroids treatment with 
IgAN by the Cox proportional hazards model.
Methods
Study population
IgA nephropathy patients were eligible for the study 
when the following criteria were satisfied: having 
received steroids therapy; age >18 years; follow-up dura-
tion >36 months. The exclusion criteria were as follows: 
24-h urinary protein excretion (UPE) >3.5 g/day; serum 
albumin (ALB) <30  g/L; pregnancy; systemic inflam-
mation, such as Henoch–Schönlein purpura; chronic 
advanced liver disease; or atypical forms of IgAN [acute 
kidney injury (AKI) associated with macroscopic hema-
turia and crescentic IgAN]. Two hundred patients with 
primary IgAN, who had been biopsied between January 
2005 and December 2010 and received steroids treat-
ment at the Department of Nephrology, Ren Ji Hospital, 
Shanghai, China, were included in this study. The study 
was approved by the Ethics Committee of Ren Ji Hospi-
tal, and all the participants gave written informed con-
sent. All the kidney biopsy slides were reviewed by an 
experienced kidney pathologist.
Study design
The influence of clinical parameters, histological grade 
and treatment on kidney survival was retrospectively 
examined. Clinical parameters and laboratory data used 
for analyses were obtained at the time of diagnosis of 
IgAN and during the follow-up, including age, gender, 
baseline systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), medical history, medications, follow-
up duration, time to remission, time to endpoint, and 
responsiveness to treatment, hemoglobin (Hb) (meas-
ured by cyanide methemoglobin method), UPE (meas-
ured by sulfosalicylic acid assay), hematuria (uRBC/HP), 
serum creatinine (SCr) (measured by ammonia imino-
hydrolase-PAP), serum uric acid (UA) (measured by a 
biosensor based on urate oxidase- peroxidase coupled 
enzyme system), blood urea nitrogen (BUN) (measured 
by urease coupling rate method), and ALB (measured by 
dye bromcresol green method).
As for the treatment, the effect of steroids therapy was 
examined. Any antihypertensive agent was permitted to 
control blood pressure during the follow-up. Using the 
modification of diet in kidney disease (MDRD) study 
equation calculated the estimated glomerular filtration 
rate (eGFR): eGFR (mL/min/1.73 m2) = 180 × [SCr (mg/
dL)]−1.154 × (age)−0.203 × (0.742 if female) [18]. Based on 
the kidney disease outcomes quality initiative (K/DOQI) 
practice guidelines, chronic kidney disease (CKD) was 
classified. The mean arterial blood pressure (MAP) was 
defined as the DBP plus one-third of the SBP. Time-aver-
aged values such as the time-averaged UPE (TA-UPE), 
the time-averaged ALB (TA-ALB), the time-averaged SCr 
(TA-SCr), and the time-averaged eGFR (TA-eGFR) were 
obtained just as previously described [19–21]. The kidney 
lesions were graded according to Lee’s classification at 
the time when the database was established [22].
After 6  months’ steroids therapy, the treatment 
response was evaluated. Complete remission (CR) was 
defined as a UPE <0.3 g/day, along with normalization of 
all biochemical findings and a lack of worsening of kid-
ney function at the sixth month; partial remission (PR) 
was defined as at least a 50% reduction in UPE at the 
sixth month compared with baseline; no response (NR) 
was defined as a <50% reduction in UPE or an increase 
in UPE with or without kidney deterioration after receiv-
ing 6 months of therapy [23]. Relapse was defined as the 
reappearance of significant proteinuria, defined as >1.0 g/
day and/or as a UPE increase of more than 50% [23, 24]. 
The end point of kidney survival was estimated by ESRD 
requiring hemodialysis therapy. The patients were classi-
fied with progression when their eGFR values decreased 
by more than 50% or when they reached ESRD during the 
follow-up period; the patients who exhibited stable kid-
ney function, defined as an eGFR that remained within 
50% of the initial value, were considered to be non-pro-
gression patients [25].
Most of the patients were treated according to the 
accepted standards at our center [12]. Long-term ACE-I 
or ARB treatment was recommended if there were no 
any contraindications. Corticosteroid was used in cases 
of massive proteinuria (>1  g/day). Corticosteroid regi-
mens in patients with IgAN were 6-month regime of oral 
prednisone starting with 0.8–1 mg/kg/day for 2 months 
and then reduced by 0.2  mg/kg/day per month for the 
next 4  months. Other immunosuppressive agents were 
considered in patients with rapidly progressing kidney 
function decline.
Statistics
Analyses of the data were carried out using SPSS soft-
ware (version 13: SPSS, Chicago, IL, USA). The normally 
distributed variables were expressed as the mean ±  SD 
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and the non-parametric variables were expressed as the 
median and range. Cox’s proportional hazards mod-
els for estimating the hazard ratios and the 95% confi-
dence intervals (CI) were used to identify the predictive 
factors for the development of IgAN progression. The 
multivariate models used a stepwise forward selection 
procedure based on a likelihood-ratio test with P > 0.10 
for the removal and P < 0.05 for the entry of the variables. 
Kidney survival was estimated with the Kaplan–Meier 
method, and comparisons were performed using the log-
rank test. Values of P less than 0.05 were considered sta-
tistically significant.
Results
Baseline characteristics of the study population
From 2005 to 2010, the data of a total of 200 patients with 
IgAN who had received steroids treatment were utilized 
in the analyses (Figure 1). All the subjects were Chinese. 
The baseline characteristics of the patients were shown in 
Table 1. The median follow-up period was 63.33 months, 
ranging from 43.60 to 100.67  months. Twenty patients 
showed progression of renal impairment after steroid 
therapy at the end of the follow-up.
The mean age at biopsy was 36.99  ±  11.33  years. 
There were 87 men and 113 women. The systolic or 
diastolic blood pressure was 124.33 ± 17.11 mmHg and 
81.08  ±  11.10  mmHg, respectively. The median and 
interquartile range (IQR) values for initial SCr were 
89.2 and 68.08–121.35 µmol/L, respectively. Sixty-seven 
patients were classified in CKD stage I, 60 in stage II, 68 
in stage III and 5 in stage IV–V. The median and IQR val-
ues for the initial ALB were 38.20 and 34.10–40.80 g/L, 
respectively. The median and IQR values for the initial 
proteinuria were 2.27 and 1.35–3.41  g/day, respectively. 
One hundred and eighty-three patients were classified in 
histological Lee’s grade III–IV.
Characteristics of the study population during follow‑up
The characteristics of the patients during the follow-up 
were shown in Table 1 as well, among which the median 
and IQR values for TA-ALB were 40.93 and 38.05–
44.14  g/L, respectively. The median and IQR values for 
TA-eGFR were 76.93 and 58.30–103.33 mL/min/1.73 m2, 
respectively. The median and IQR values for TA-UPE 
were 0.89 and 0.51–1.75 g/day, respectively.
Finally, a total of 160 patients with IgAN achieved 
remission within 6 months of initiation of steroids ther-
apy. The remaining 40 patients (20.0%) exhibited a mini-
mal response or NR. Additionally, 17.3% of the remission 
patients experienced relapse during the follow-up. Dur-
ing the median follow-up period of 63.33 months, 10.0% 
of the 200 included patients met the criteria of progres-
sion in this study.
Risk factors for the development of kidney progression 
in IgAN patients receiving steroids treatment
Both univariate and multivariate Cox analyses were per-
formed to evaluate the impact of the potential predictors 
on kidney progression in IgAN patients receiving steroids 
treatment. As shown in Table 2, age, baseline ALB, base-
line eGFR, response to therapy (non-remission vs remis-
sion and relapse vs non-relapse), ALB at month 6,UPE at 
month 3,UPE at month 6, TA-ALB, TA-eGFR, and TA-
UPE were notably associated with the risk of kidney pro-
gression in the univariate analyses.
Those factors that were significantly correlated 
with progression on the basis of univariate analy-
ses were further evaluated by the multivariate analy-
ses. Three multivariate Cox regression models were 
created, as shown in Table  3. In model 1, higher TA-
ALB and higher TA-eGFR reduced the risk of occur-
ring kidney function deterioration independently. As 
for the steroids treatment, hazard ratio (HR) for kid-
ney progression of non-remission patients after ster-
oids therapy increased significantly compared to the 
remission group (HR = 5.877, 95% CI = 2.031–17.006, 
P  =  0.001). These findings were still observed in 
model 2 after adjusting for the effects of age, gender, Figure 1 A flow diagram of the study.
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eGFR, ALB, and UPE (HR =  4.995, 95% CI =  1.436–
17.365, p = 0.011). In the adjusted model, individuals 
who experienced relapse had a greater risk of kidney 
progression compared with non-relapse individuals 
(HR  =  12.629, 95% CI  =  1.446–110.320, p  =  0.021) 
(Table 3, model 3).
Table 1 Characteristics and clinical outcome in 200 IgAN patients receiving glucocorticoid medicine therapy
Characteristics All included patients (N = 200) Non‑progression patients (N = 180) Progression patients (N = 20)
Baseline
 Age (years) 36.99 ± 11.33 36.20 ± 10.42 43.93 ± 16.34
 Gender: female, n (%) 113 (56.5) 100 (55.60) 13 (64.30)
 SBP (mm Hg) 124.33 ± 17.11 124.08 ± 16.08 126.43 ± 24.99
 DBP (mm Hg) 81.08 ± 11.10 81.33 ± 10.89 78.93 ± 13.04
 SCr (µmol/L) 89.2 (68.08–121.35) 88.25 (67.35–117.70) 108.95 (84.80–139.40)
 eGFR (mL/min/1.73 m2) 70.98 (51.91–95.93) 72.84 (52.93–96.39) 53.36 (46.55–62.35)
 BUN (mmol/L) 5.98 (4.60–7.80) 5.90 (4.60–7.40) 6.78 (5.46–8.94)
 UA (µmol/L) 363.00 (311.65–427.50) 359.00 (310.00–422.00) 380.50 (347.00–436.00)
 Hb (g/L) 131.00 (120.00–143.00) 132.50 (120.00–144.00) 124.00 (121.00–132.00)
 ALB (g/L) 38.20 (34.10–40.80) 38.40 (34.60–41.10) 33.75 (30.20–38.60)
 UPE (g/day) 2.27 (1.35–3.41) 2.14 (1.34–3.14) 3.08 (2.27–3.84)
 uRBC/HP 26.20 (8.03–67.48) 24.10 (7.80–66.55) 31.00 (12.30–51.70)
 CKD stage, n (%)
  Stage I 67 (33.5) 63 (35.0) 4 (20.0)
  Stage II 60 (30.0) 57 (31.6) 3 (15.0)
  Stage III 68 (34.0) 55 (30.6) 13 (65.0)
  Stage IV–V 5 (2.5) 5 (2.8) 0 (0)
  FSGS, n (%) 112 (56.0)
 Renal biopsy Lee’s classification, n (%)
  Grade I 4 (2.1) 3 (1.7) 1 (5.0)
  Grade II 4 (2.1) 2 (1.1) 2 (10.0)
  Grade III 115 (57.4) 103 (57.2) 12 (60.0)
  Grade IV 68 (34.0) 65 (36.1) 3 (15.0)
  Grade V 9 (4.3) 7 (3.9) 2 (10.0)
Follow-up
 Remission, n (%) 160 (80) 152(84.4) 8 (40.0)
 Complete remission, n (%) 71 (35.4) 68 (37.8) 3 (15.0)
 Partial remission, n (%) 89 (44.6) 84 (46.7) 5 (25.0)
 Non-response, n (%) 40 (20.0) 28 (15.6) 12 (60.0)
 Relapse, n (%) 35 (17.3) 24 (13.3) 11 (55.0)
 Progression, n (%) 20 (10)
 Length of follow-up (months) 68.33 (43.60–100.67) 67.33 (42.93–98.77) 71.42 (38.37–92.83)
 ALB (g/L) at month 3 39.45 (35.80–43.03) 40.00 (35.90–43.30) 37.50 (35.00–40.00)
 ALB (g/L) at month 6 41.50 (37.50–44.15) 42.20 (38.10–45.00) 36.75 (35.20–40.00)
 TA-ALB (g/L) 40.93 (38.05–44.14) 42.48 (38.75–44.65) 37.28 (36.40–39.01)
 SCr (µmol/L) at month 3 88.10 (71.60–105.00) 87.30 (71.60–104.80) 101.55 (78.80–112.20)
 SCr (µmol/L) at month 6 80.00 (64.70–104.50) 79.00 (64.70–100.60) 97.85 (78.00–128.50)
 TA-SCr (µmol/L) 85.24 (64.81–106.75) 83.73 (64.71–103.46) 99.34 (77.36–111.91)
 eGFR (mL/min/1.73 m2) at month 3 70.34 (56.97–98.72) 73.67 (58.04–98.72) 61.98 (48.87–81.43)
 eGFR (mL/min/1.73 m2) at month 6 80.02 (58.05–103.28) 81.08 (62.52–103.38) 58.68 (52.57–82.39)
 TA-eGFR (mL/min/1.73 m2) 76.93 (58.30–103.33) 80.61 (59.49–104.98) 58.74 (52.66–83.32)
 UPE (g/day) at month 3 0.79 (0.36–1.94) 0.73 (0.36–1.57) 1.26 (0.60–2.52)
 UPE (g/day) at month 6 0.63 (0.21–1.51) 0.60 (0.19–1.39) 1.36 (0.72–2.29)
 TA-UPE (g/day) 0.89 (0.51–1.75) 0.83 (0.49–1.69) 2.11 (0.82–2.36)
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Based on the Kaplan–Meier analyses, the actual kid-
ney survival according to the potential risk factors 
were plotted in Figures  2, 3, 4 and 5. As illustrated in 
 Figure 2, remission patients (CR or PR patients) had sig-
nificantly longer progression-free times compared with 
the non-remission patients (P < 0.05). The patients who 
experienced relapse after achieving remission, had an 
unfavorable survival rate of non-progression (Figure  3). 
The relationship between the TA-ALB values and kid-
ney outcomes was dramatically altered at levels of 40 and 
35 g/L. And the relationship between the TA-eGFR lev-
els and kidney outcomes was altered at levels of 90 and 
60 mL/min/1.73 m2 (Figures 4, 5).
Discussion
Long-term prognosis of IgAN was highly variable: ESRD 
occurred in 5–25% of cases within 10 years [2, 3, 26] and 
in 25–50% within 20  years [3]. There were a variety of 
studies having confirmed the effect of steroids treatment 
on amelioration of the clinical course of IgAN [14, 15]. 
In clinical practice, beneficial effects from the short-term 
use of corticosteroids in the small sample of patients 
were clear and definite. However, the long-term efficacy 
of steroids therapy in IgAN had barely been testified,and 
a number of IgAN patients progressed to ESRD even 
having received steroids therapy. RCT studies have con-
firmed that 50% increase in plasma creatinine from 
baseline occurred in about 10% of IgAN patients within 
4–5  years of starting steroids treatment [10, 27, 28]. 
Similarly, kidney progression occurred in 20/200 (10%) 
included patients of this study. Thus the aim of this study 
was to identify risk factors for kidney function dete-
rioration in a cohort of IgAN patients receiving steroids 
treatment.
Among the clinical and laboratory indicators of the 
disease, persistent and severe proteinuria was identified 
as the most important predictor of a poor outcome [2, 3, 
6–8] and that its reduction correlates with better kidney 
function. A long-term RCT of 86 adult IgAN patients 
evaluating corticosteroids effectiveness in IgA nephrop-
athy showed that, in addition to steroids, a reduction in 
proteinuria levels after 6 months, and no increase in pro-
teinuria during follow-up all were independent predic-
tors of a beneficial outcome [13].
Results of this study demonstrated that proteinuria at 
month 3 and month 6 was a strong related factor of kid-
ney function decline in patients with IgAN according to 
univariate analysis. After a multivariate Cox analysis, we 
were unable to provide clear evidence that proteinuria 
was associated with kidney outcomes. This parameter did 
not independently contribute to the risk in the multivari-
ate models.
Instead, the adjusted multivariate Cox analysis model 
revealed that non-remission state was associated with 
a 3.995 folds of increase in the risk of kidney progres-
sion, confirming the importance of proteinuria reduction 
in retarding IgAN progression. A recent multi-center 
RCT assessing whether the combination of prednisone 
and ramipril was more effective than ramipril alone in 
patients with proteinuric IgAN, revealed that a decrease 
in 24-h proteinuria <1  g was observed in 36/48 (75.0%) 
patients of the combination therapy group and in 33/49 
(67.3%) patients of the monotherapy group at 6 months 
of follow-up [14]. In this study, CR and PR were achieved 
in 71 (35.4%) and 89 (44.6%) patients, respectively. 
The remaining 20.0% patients presented persistent 
proteinuria.
Relapse of proteinuria was commonly seen in IgAN 
patients. In this study, 28/160 (17.3%) patients appeared 
relapse after achieving remission, and individuals who 
experienced relapse had a significantly increased risk of 
kidney progression after adjusting for the effects of age, 
gender, eGFR, ALB, and UPE. This result verified previ-
ous viewpoint as well [13].
Serum albumin was a biomarker of nutritional status 
and inflammation [29]. In our previous study, we had 
Table 2 Factors that were found to affect the long-term 
prognosis in IgAN patients receiving glucocorticoid medi-
cine therapy in the univariate COX regression analyses
Characteristics Univariate analysis
HR 95% CI P value
Baseline
 Age (years) 1.063 1.014–1.115 0.011
 ALB (g/L) 0.929 0.869–0.994 0.033
 eGFR (mL/min/1.73 m2) 0.976 0.953–1.000 0.047
 uRBC/HP 0.975
 Renal biopsy Lee’s classification, n (%)
  Grade I
  Grade II
  Grade III
  Grade IV 0.596
Follow-up
 Length of follow-up (months) 0.684
 Non-remission (vs remission) 5.877 2.031–17.006 0.001
 Relapse (vs non-relapse) 12.602 1.443–110.058 0.022
 ALB g/L at month 6 0.844 0.761–0.935 0.001
 UPE at month 3 (g/day) 1.000 1.000–1.001 0.016
 UPE at month 6 (g/day) 1.000 1.000-1.001 0.043
 uRBC/HP at month 3 0.961
 uRBC/HP at month 6 0.574
 TA-ALB (g/L) 0.778 0.663–0.913 0.002
 TA-eGFR (mL/min/1.73 m2) 0.978 0.957–1.000 0.048
 TA-UPE (g/day) 1.000 1.000–1.001 0.046
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demonstrated that the TA-ALB value was an independ-
ent predictor of kidney progression in IgAN patients 
who had achieved remission after treatment [19]. In the 
present study, baseline ALB, ALB at month 6 and TA-
ALB correlated with kidney function decline in patients 
receiving steroids therapy by the univariate analysis. This 
result was in accordance with findings observed across 
multiple cohorts [20, 30–32].
Damaged baseline eGFR was a traditional risk factor for 
kidney progression. Similar to prior reports [3, 20, 33–35], 
we confirmed that the baseline eGFR and TA-eGFR were 
associated with kidney progression among IgAN patients 
Table 3 Factors that were found to affect the long-term prognosis in IgAN patients receiving glucocorticoid medicine 
therapy in the multivariate COX regression analyses
Characteristics Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Model 1 (n = 200)
 Age (years) 1.063 1.014–1.115 0.011 0.20
 Gender 0.48 0.42
 TA-eGFR (mL/min/1.73 m2) 0.978 0.957–1.000 0.048 0.971 0.945–0.998 0.03
 TA-ALB (g/L) 0.778 0.663–0.913 0.002 0.772 0.636–0.937 0.008
 UPE at month 3 (g/day) 1.000 1.000–1.001 0.016 0.40
Model 2 (n = 200)
 Age (years) 1.063 1.014–1.115 0.011 0.25
 Gender 0.48 0.32
 Non-remission (vs remission) 5.877 2.031–17.006 0.001 4.995 1.436–17.365 0.011
 TA-eGFR (mL/min/1.73 m2) 0.978 0.957–1.000 0.048 0.962 0.933–0.992 0.013
 TA-ALB (g/L) 0.778 0.663–0.913 0.002 0.806 0.673–0.966 0.019
 UPE at month 3 (g/day) 1.000 1.000–1.001 0.016 0.99
Model 3 (n = 160)
 Age (years) 1.063 1.014–1.115 0.011 0.52
 Gender 0.48 0.13
 Relapse (vs non-relapse) 12.602 1.443–110.058 0.022 12.629 1.446–110.32 0.021
 TA-eGFR (mL/min/1.73 m2) 0.978 0.957–1.000 0.048 0.06
 TA-ALB (g/L) 0.778 0.663–0.913 0.002 0. 12
 UPE at month 3 (g/day) 1.000 1.000–1.001 0.016 0.28
Figure 2 Progression-free survival analysis according to remission.
Figure 3 Progression-free survival analysis according to relapse.
Page 7 of 8Yuan et al. J Transl Med  (2015) 13:186 
receiving steroids treatment. Uncontrolled hypertension 
during follow-up is associated with greater proteinuria and 
predicts a faster GFR decline. Patients included in our study 
were monitored closely and under strict blood pressure 
control. Most patients had been kept within the normal 
blood pressure range after ACEIs/ARBs treatment during 
long term follow-up. Some studies had identified that elder 
patients would progressed to ESRD more promptly [2, 36–
38]. Our multivariate analysis also suggested that older age 
at diagnosis was a strong predictor of kidney progression 
among patients having received steroids therapy.
This is a study to use a cohort of IgAN patients having 
received steroids treatment after diagnose to assess kid-
ney outcomes and the related risk factors for kidney pro-
gression. Our study may help explain the reason of a large 
number of patients receiving prednisone still progressed to 
ESRD. This study is unique in that it identified predictors for 
clinical outcomes among a pool of IgAN patients receiving 
steroids therapy. The strengths of this study also included a 
relative large number of IgAN patients, a uniform therapy 
strategy, and the robust database. Using this robust data-
base, we examined the impact that clinical patterns have 
on progression to ESRD. Several shortcomings of this study 
existed. This study was a retrospective study and most of the 
patients recruited came from the southern regions of China. 
Therefore, the analyses had an inherent selection bias and 
limited representation. Thus, more studies are required to 
evaluate the progression of IgAN in patients under steroids 
treatment regimen in the future.
Conclusions
In summary, our data clearly showed that relapse, non-
remission, TA-eGFR, and TA-ALB were associated with 
renal outcomes. Furthermore, these characteristics could 
serve as independent predictors of long term prognosis 
of IgAN patients receiving corticosteroid therapy.
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Figure 4 Progression-free survival analysis according to TA-eGFR.
Figure 5 Progression-free survival analysis according to TA-ALB.
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